Understanding this GLP-1 microbiome connection is the difference between viewing your symptoms as temporary discomfort that resolves on its own and recognizing persistent digestive dysfunction that requires targeted support
Knowing these conditions can help people understand what may be happening in their body
The NICE criteria are as follows: NICE recommends GLP-1 analogues or Tirzepatide (Mounjaro) for the treatment of adults with type 2 diabetes alongside diet and exercise when diabetes is insufficiently controlled, only if: triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and a person has a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or a person has a BMI of less than 35 kg/m2, and: Insulin therapy would have significant occupational implications, or Weight loss would benefit other significant obesity-related complications
In a previous systematic review of weight regain following behavioural weight management programmes, Hartmann-Boyce et al (2023a) identified that, after a mean weight loss of 2.4 kg, weight regain occurred at a rate of 0.02 kg per month, with evidence of cardiometabolic benefit persisting for 5 years
